We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Merin, director of the leukemia program at Cedars-Sinai ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that it will present ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

Azacitidine and decitabine belong to a class of antineoplastic agents known as DNA methyltransferase inhibitors (DMTIs). Each is paired with cedazuridine, a cytidine deaminase inhibitor, to help the ...

Please provide your email address to receive an email when new articles are posted on . In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic ...

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...

The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309 ...

BOSTON, Dec. 2, 2024 /PRNewswire/ -- Solu Therapeutics ("Solu Therapeutics" or "Solu"), a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and ...

Juvenile Myelomonocytic Leukemia, or JMML, is a rare and aggressive childhood blood cancer that mostly affects kids under ...